StockTitan

@stocktitan.net

1 month ago

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q4 2025 net revenue of $247.1M (+29.6% YoY) and full‑year revenue of $883.4M (+43.8% YoY). Cortrophin Gel drove Rare Disease growth with Q4 revenue of $111.4M (+87.6%) and full‑year $347.8M (+75.6%).The company posted Q4 GAAP EPS $1.18 and adjusted non‑GAAP diluted EPS $2.33, record adjusted EBITDA of $65.4M Q4 and $229.8M full year, and reaffirmed 2026 guidance targeting >$1B revenue and adjusted EBITDA $275M–$290M.

#ANIP ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

www.stocktitan.net/news/ANIP/ani-pharmaceut...

TickerTalksAI

@tickertalksai.bsky.social

2 months ago

💼 $ANIP beats 2025 EPS guidance with $7.37-$7.64 vs $6.97 consensus | 2026 revenue forecast $1.055B-$1.115B | Cortrophin Gel +76% YoY | Rare Disease now ~60% of revenue

StockTitan

@stocktitan.net

2 months ago

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with

#ANIP ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

4 months ago

ANI Pharmaceuticals Announces Board Transition ANI Pharmaceuticals (Nasdaq: ANIP) announced a Board leadership change on Dec 1, 2025. Patrick D. Walsh has stepped down as Chairman and will retire from the board after completing his current term at the Company’s 2026 Annual Meeting of Stockholders. The Board unanimously elected Thomas J. Haughey, a director since May 2018, as the next Chairman. Mr. Haughey will relinquish the role of Chair of the Audit and Finance Committee and remain on that committee and the Nominating and Corporate Governance Committee.Jeanne Thoma, a director since August 2020, will become Chair of the Audit and Finance Committee. Management framed the transition as orderly and focused on continuity while the company expands its Rare Disease business.

#ANIP ANI Pharmaceuticals Announces Board Transition

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

4 months ago

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjusted non-GAAP EBITDA of $59.6 million, an increase of 69.8% year-over-year Diluted GAAP income per

#ANIP ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

5 months ago

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN ® (fluocinolone

#ANIP ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

www.stocktitan.net/news/ANIP/ani-pharmaceut...

Motor Show Online

@motorshow.bsky.social

6 months ago

Governo barra pedido da indústria brasileira que deixaria pneus importados mais caros; entenda Governo federal barrou o pedido da Associação Nacional da Indústria de Pneumáticos para elevar de 25% para 35% a alíquota do imposto de importação sobre os pneus de automóveis de passageiros; no entan...

Governo federal barrou o pedido da Associação Nacional da Indústria de Pneumáticos para elevar de 25% para 35% a alíquota do imposto de importação sobre os pneus de automóveis de passageiros

#pneus #ANIP #ABIDIP

motorshow.com.br/aumento-de-i...

Ani Meida 🩷⚡️

@animeida.happydevilgirl.dev

7 months ago

I LOVE YOU TOO FRIENDDDDDD AAAAAAAAHHHHHH!!!! I’m incredibly grateful that you accepted !!! I can’t wait to make more stuff with you in the future. Rin is INCREDIBLE!!!! There will be much more Vocaloid from me!!! #AniP

StockTitan

@stocktitan.net

7 months ago

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance ANI Pharmaceuticals (NASDAQ:ANIP) reported exceptional Q2 2025 results with record-breaking performance across key metrics. The company achieved total net revenues of $211.4 million, representing 53.1% year-over-year growth. Their Rare Disease segment, led by Cortrophin Gel with $81.6 million in revenue (66% YoY growth), was a major contributor.The company's Generics business generated $90.3 million in revenue, up 22.1% YoY. ANI delivered record quarterly adjusted EBITDA of $54.1 million, a 62.8% increase, and achieved adjusted non-GAAP diluted EPS of $1.80.Based on strong performance, ANI raised its 2025 guidance, now expecting total revenues of $818-843 million and adjusted non-GAAP EBITDA of $213-223 million. Rare Disease revenues are projected to represent approximately 50% of total company revenues in 2025.

#ANIP ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

8 months ago

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) ANI Pharmaceuticals (NASDAQ:ANIP) announced results from the NEW DAY clinical trial evaluating ILUVIEN® for diabetic macular edema (DME) treatment. The study compared ILUVIEN to aflibercept in treatment-naïve patients.The trial's primary endpoint of reducing supplemental aflibercept injections was not met in the intent-to-treat population (2.4 vs 2.5 injections, p=0.756). However, a secondary endpoint showed significantly longer time between treatments with ILUVIEN (185.4 vs 132.8 days, psignificant reduction in supplemental injections for the ILUVIEN group (1.8 vs 2.5, p=0.029).Safety data showed ILUVIEN was well-tolerated but had higher treatment-related adverse events (41%) compared to aflibercept (3%), mainly related to cataracts and increased intraocular pressure.

#ANIP ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

9 months ago

ANI Pharmaceuticals Announces Presentation of New Preclinical Data ANI Pharmaceuticals presented new preclinical data for Purified Cortrophin Gel at EULAR 2025 Congress, demonstrating promising results in treating murine collagen-induced arthritis. The study showed that repository corticotropin injection (RCI) significantly reduced joint swelling and inflammatory cytokine response in mice, particularly at the 400 U/kg dose, without causing additional bone loss. The research, led by experts from UC San Diego and UC Davis, supports ANI's commitment to understanding their product's mechanism of action. Cortrophin Gel is currently indicated for short-term administration as adjunctive therapy in rheumatoid arthritis, including juvenile rheumatoid arthritis.

#ANIP ANI Pharmaceuticals Announces Presentation of New Preclinical Data

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

10 months ago

ANIP - Ani Pharmaceutic Latest Stock News & Market Updates ANI Pharmaceuticals (ANIP) news hub: Track press releases, FDA updates & financial reports for specialty generics, complex formulations, and rare disease therapies.

#ANIP ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

10 months ago

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance ANI Pharmaceuticals (ANIP) reported exceptional Q1 2025 financial results and raised its full-year guidance. The company achieved record quarterly revenues of $197.1 million, up 43.4% year-over-year. Key highlights include Rare Disease revenues of $69.0 million, with Cortrophin Gel generating $52.9 million (+43.1% YoY) and ILUVIEN/YUTIQ contributing $16.1 million. Generics revenue grew 40.5% to $98.7 million. The company delivered record adjusted EBITDA of $50.7 million (+34.9% YoY) and adjusted EPS of $1.70. Based on strong performance, ANI raised its 2025 guidance, now expecting revenues of $768-793 million and adjusted EPS of $6.27-6.62. The company maintains a strong U.S. footprint with over 90% of revenues from U.S.-manufactured goods.

#ANIP ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

11 months ago

Breakthrough: ANI's Cortrophin Gel Achieves Dose-Dependent Success in Autoimmune Eye Disease Trial Latest preclinical data reveals Cortrophin Gel's significant impact on autoimmune uveitis. See detailed efficacy results across four dose levels presented at ARVO 2025.

#ANIP ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

www.stocktitan.net/news/ANIP/ani-pharmaceut...

Motor Show Online

@motorshow.bsky.social

11 months ago

O mercado nacional se tornará um dos principais destinos para pneus de países que perderão competitividade no mercado norte-americano

#pneu #pneusnovos #pneus #pneusdequalidade #pneusimportados #Anip #Abidip

motorshow.com.br/importacao-d...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Most searched small-cap stocks, Thu Apr 17th - #PTEN #TGL #FNA #RIOT #UUUU #AGL #BBAI #APLD #JBLU #RIG #ZIM #WOLF #WKEY #TGB #UAA #QBTS #OKLO #HTZ #ANIP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

ANI Pharma's Strategic $17M Move Boosts Profit Potential for Eye Drug Portfolio Strategic buyout eliminates 3.125% royalty on ILUVIEN and YUTIQ revenues, enhancing future profitability. Cash-funded deal showcases ANI's financial strength in retina portfolio.

#ANIP ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label ANI Pharmaceuticals (ANIP) has received FDA approval for an expanded label of ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to its existing diabetic macular edema (DME) indication.The company plans to market ILUVIEN for both indications in the U.S. later this year. The treatment is already approved for both DME and NIU-PS in seventeen European countries. ANI has extended its supply agreement with Siegfried through 2029, including plans to upgrade equipment and expand manufacturing capacity.ILUVIEN is specifically indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise, and for chronic NIU-PS treatment. The treatment carries important safety considerations, including risks of infection, increased intraocular pressure, cataracts, and delayed wound healing.

#ANIP ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe ANI Pharmaceuticals (ANIP) has received FDA approval for a new prefilled syringe format of Purified Cortrophin® Gel, a repository corticotropin injection. The new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through established specialty pharmacy networks.The prefilled syringe format simplifies administration for patients while maintaining the existing vial options. The product launch is scheduled for the second quarter of 2025. Cortrophin Gel is indicated for various conditions including acute gouty arthritis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, severe psoriasis, and acute exacerbations of multiple sclerosis.

#ANIP ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8% Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, and

#ANIP ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Earnings: Rare Disease Portfolio Performance and 2025 Growth Strategy Revealed Join ANI Pharmaceuticals' leadership team on February 28 as they unveil Q4 and FY2024 results, discussing rare disease progress and strategic initiatives.

#ANIP ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

Alcami Announces CEO Transition as Chairman Patrick Walsh Steps in as Interim Chief Executive Contract development and manufacturing leader Alcami names Chairman Patrick Walsh as Interim CEO following Bill Humphries' departure after two years of expansion.

#ANIP Alcami Announces CEO Transition

www.stocktitan.net/news/ANIP/alcami-announc...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Projects Strong 25% Growth for 2025, Exceeds 2024 Guidance Targets ANI Pharmaceuticals forecasts robust 2025 revenue of $739-759M, driven by Rare Disease success and newly acquired eye treatments ILUVIEN and YUTIQ performing well.

#ANIP ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

ANI Pharmaceuticals Launches First Generic Motegrity with Exclusive 180-Day Market Access ANI Pharmaceuticals secures FDA approval for Prucalopride Tablets, targeting $168M market as first generic alternative to Motegrity with 180-day exclusivity period.

#ANIP ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

www.stocktitan.net/news/ANIP/ani-pharmaceut...

StockTitan

@stocktitan.net

1 year ago

#ANIP ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/ANIP/ani-pharmaceut...

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #ANIP ) Overweight Recommendation Issued On ANIP By Piper Sandler

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #ANIP ) ANIP Price Target Alert: $83.00. Issued by Raymond James

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #ANIP ) Outperform Recommendation Issued On ANIP By Raymond James

#StockMarket #News